Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, NDA Approval, Therapies, ROA, MOA and Companies by DelveInsight

Globe and Mail

11-03-2025

"Non-Cystic Fibrosis Bronchiectasis Pipeline"
Non-Cystic Fibrosis Bronchiectasis companies in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others.
(Albany, USA) 'Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2025' report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Cystic Fibrosis Bronchiectasis Market.
The Non-Cystic Fibrosis Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
As per DelveInsight's assessment, globally, Non-Cystic Fibrosis Bronchiectasis pipeline constitutes 16+ key companies continuously working towards developing 17+ Non-Cystic Fibrosis Bronchiectasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
Some of the key takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report:
NCFB Companies across the globe are diligently working toward developing novel Non-Cystic Fibrosis Bronchiectasis treatment therapies with a considerable amount of success over the years.
Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others, are developing therapies for the Non-Cystic Fibrosis Bronchiectasis treatment.
Emerging Non-Cystic Fibrosis Bronchiectasis therapies in the different phases of clinical trials are- NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others are expected to have a significant impact on the Non-Cystic Fibrosis Bronchiectasis market in the coming years.
In February 2025, Insmed Incorporated announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Brensocatib for patients with non-cystic fibrosis bronchiectasis.
In October 2024, Insmed shared positive late-breaking subgroup data from the Phase III ASPEN study of brensocatib for patients with NCFB at the CHEST 2024 Annual Meeting.
In July 2024, Armata Pharmaceuticals stated that it had completed enrollment in its Tailwind Phase 2 clinical trial of inhaled AP-PA02 in patients with NCFB and chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection.
In May 2024, Insmed Incorporated reported encouraging topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 trial to evaluate brensocatib's effectiveness, safety, and tolerability in patients with non-cystic fibrosis bronchiectasis. The study accomplished its primary aim, with both brensocatib dose strengths showing statistically significant reductions in the annualized rate of pulmonary exacerbations (PEs) compared to placebo. The study also met several of its predetermined secondary goals with statistical significance.
In July 2023, Zambon, a global pharmaceutical company dedicated to innovating treatments and enhancing the health and well-being of patients, revealed the conclusive findings from the Phase 3 PROMIS-I and PROMIS-II studies. These results were unveiled during the 2023 6th World Bronchiectasis Conference held in New York, NY.
In December 2022, Haisco Pharmaceutical Group Co., Ltd. has commenced a trial titled 'Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study.' This study aims to evaluate the effectiveness and safety of HSK31858 in individuals diagnosed with Non-cystic Fibrosis Bronchiectasis.
In April 2022, The FDA awarded breakthrough therapy designation to colistimethate sodium powder intended for nebulization solution to alleviate pulmonary exacerbations in adults afflicted with Non-cystic fibrosis bronchiectasis and Pseudomonas aeruginosa. The basis for the FDA's breakthrough therapy designation was supported by findings from the phase III PROMIS-I study, showcasing that CMS I-neb notably decreased annual rates of pulmonary exacerbations compared to a placebo within this patient population.
Non-Cystic Fibrosis Bronchiectasis Overview
Non-Cystic Fibrosis Bronchiectasis (NCFBE) is a chronic lung condition characterized by permanent dilation and damage of the bronchi, leading to impaired mucus clearance and recurrent infections. Unlike cystic fibrosis-related bronchiectasis, NCFBE is caused by underlying conditions such as chronic infections, autoimmune diseases, primary ciliary dyskinesia, allergic bronchopulmonary aspergillosis (ABPA), or immune deficiencies.
Patients with NCFBE experience persistent cough, excessive mucus production, recurrent respiratory infections, and shortness of breath, fatigue, and wheezing. The accumulation of mucus creates a breeding ground for bacteria, leading to frequent exacerbations and lung function decline. Common pathogens, including Pseudomonas aeruginosa and Haemophilus influenzae, contribute to disease progression and complications.
Non-Cystic Fibrosis Bronchiectasis Diagnosis involves high-resolution computed tomography (HRCT) scans, pulmonary function tests, sputum cultures, and blood tests to identify underlying causes. Non-Cystic Fibrosis Bronchiectasis Treatment focuses on airway clearance therapies, bronchodilators, inhaled antibiotics, corticosteroids, and mucolytics to reduce symptoms and prevent exacerbations. Pulmonary rehabilitation, vaccination, and lifestyle modifications also play a crucial role in disease management. While NCFBE is a chronic and progressive condition, advancements in targeted therapies, biologics, and precision medicine are improving patient outcomes, reducing exacerbations, and enhancing quality of life.
Emerging Non-Cystic Fibrosis Bronchiectasis Drugs Under Different Phases of Clinical Development Include:
Non-Cystic Fibrosis Bronchiectasis Route of Administration
Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intravenous
Subcutaneous
Oral
Intramuscular
Non-Cystic Fibrosis Bronchiectasis Molecule Type
Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types, such as
Monoclonal antibody
Small molecule
Peptide
Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics Assessment
Non-Cystic Fibrosis Bronchiectasis Assessment by Product Type
Non-Cystic Fibrosis Bronchiectasis By Stage and Product Type
Non-Cystic Fibrosis Bronchiectasis Assessment by Route of Administration
Non-Cystic Fibrosis Bronchiectasis By Stage and Route of Administration
Non-Cystic Fibrosis Bronchiectasis Assessment by Molecule Type
Non-Cystic Fibrosis Bronchiectasis by Stage and Molecule Type
DelveInsight's Non-Cystic Fibrosis Bronchiectasis Report covers around 17+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Non-Cystic Fibrosis Bronchiectasis product details are provided in the report. Download the Non-Cystic Fibrosis Bronchiectasis pipeline report to learn more about the emerging Non-Cystic Fibrosis Bronchiectasis therapies @ Non-Cystic Fibrosis Bronchiectasis Treatment Market
Some of the key companies in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market include:
Key companies developing therapies for Non-Cystic Fibrosis Bronchiectasis are – Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Haisco Pharmaceutical, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, and others.
Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis:
The Non-Cystic Fibrosis Bronchiectasis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment.
Non-Cystic Fibrosis Bronchiectasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Non-Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis drugs and therapies – Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Advancements
Non-Cystic Fibrosis Bronchiectasis Pipeline Market Drivers
Recent Developments to Improve Research into Bronchiectasis, emergence of Novel Drugs & Therapies with Great Market Potential are some of the important factors that are fueling the Non-Cystic Fibrosis Bronchiectasis Market.
Non-Cystic Fibrosis Bronchiectasis Pipeline Market Barriers
However, challenges Associated with the Drug Delivery, regulatory & Economic Hindrance and other factors are creating obstacles in the Non-Cystic Fibrosis Bronchiectasis Market growth.
Scope of Non-Cystic Fibrosis Bronchiectasis Pipeline Drug Insight
Coverage: Global
Key Non-Cystic Fibrosis Bronchiectasis Companies: NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others
Key Non-Cystic Fibrosis Bronchiectasis Therapies: NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others
Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging therapies
Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market barriers
Table of Contents
1. Non-Cystic Fibrosis Bronchiectasis Report Introduction
2. Non-Cystic Fibrosis Bronchiectasis Executive Summary
3. Non-Cystic Fibrosis Bronchiectasis Overview
4. Non-Cystic Fibrosis Bronchiectasis- Analytical Perspective In-depth Commercial Assessment
5. Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics
6. Non-Cystic Fibrosis Bronchiectasis Late Stage Products (Phase II/III)
7. Non-Cystic Fibrosis Bronchiectasis Mid Stage Products (Phase II)
8. Non-Cystic Fibrosis Bronchiectasis Early Stage Products (Phase I)
9. Non-Cystic Fibrosis Bronchiectasis Preclinical Stage Products
10. Non-Cystic Fibrosis Bronchiectasis Therapeutics Assessment
11. Non-Cystic Fibrosis Bronchiectasis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Non-Cystic Fibrosis Bronchiectasis Key Companies
14. Non-Cystic Fibrosis Bronchiectasis Key Products
15. Non-Cystic Fibrosis Bronchiectasis Unmet Needs
16 . Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers
17. Non-Cystic Fibrosis Bronchiectasis Future Perspectives and Conclusion
18. Non-Cystic Fibrosis Bronchiectasis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: [phone]
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting